These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 17489980)

  • 1. Gene silencing by DNA methylation in haematological malignancies.
    Boultwood J; Wainscoat JS
    Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
    Esteller M
    Oncogene; 2002 Aug; 21(35):5427-40. PubMed ID: 12154405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fundamental role of epigenetics in hematopoietic malignancies.
    Galm O; Herman JG; Baylin SB
    Blood Rev; 2006 Jan; 20(1):1-13. PubMed ID: 16426940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.
    Galm O; Wilop S; Lüders C; Jost E; Gehbauer G; Herman JG; Osieka R
    Ann Hematol; 2005 Dec; 84 Suppl 1():39-46. PubMed ID: 16231140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation and gene silencing in cancer: which is the guilty party?
    Clark SJ; Melki J
    Oncogene; 2002 Aug; 21(35):5380-7. PubMed ID: 12154400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis.
    Clark SJ
    Hum Mol Genet; 2007 Apr; 16 Spec No 1():R88-95. PubMed ID: 17613553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
    Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
    Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
    Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
    Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of gene promoters in hematological neoplasia.
    Chim CS; Liang R; Kwong YL
    Hematol Oncol; 2002 Dec; 20(4):167-76. PubMed ID: 12469326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of the MGMT gene in cancer.
    Soejima H; Zhao W; Mukai T
    Biochem Cell Biol; 2005 Aug; 83(4):429-37. PubMed ID: 16094446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic changes in solid and hematopoietic tumors.
    Toyota M; Issa JP
    Semin Oncol; 2005 Oct; 32(5):521-30. PubMed ID: 16210093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation.
    Jacinto FV; Ballestar E; Esteller M
    Oncogene; 2009 Nov; 28(47):4212-24. PubMed ID: 19734945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA hypermethylation: when tumour suppressor genes go silent.
    Garinis GA; Patrinos GP; Spanakis NE; Menounos PG
    Hum Genet; 2002 Aug; 111(2):115-27. PubMed ID: 12189484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of DNA hypermethylation in human neoplasia.
    Toyota M; Issa JP
    Electrophoresis; 2000 Jan; 21(2):329-33. PubMed ID: 10675010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant gene promoter methylation in plasma cell dyscrasias.
    Martin P; Garcia-Cosio M; Santon A; Bellas C
    Exp Mol Pathol; 2008 Jun; 84(3):256-61. PubMed ID: 18410922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies.
    Ying J; Gao Z; Li H; Srivastava G; Murray PG; Goh HK; Lim CY; Wang Y; Marafioti T; Mason DY; Ambinder RF; Chan AT; Tao Q
    Br J Haematol; 2007 Mar; 136(6):829-32. PubMed ID: 17341268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of bidirectional promoters by DNA methylation in tumorigenesis.
    Shu J; Jelinek J; Chang H; Shen L; Qin T; Chung W; Oki Y; Issa JP
    Cancer Res; 2006 May; 66(10):5077-84. PubMed ID: 16707430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.